



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Bernard R. Brodeur et al.
Application No. : 09/684,883
Filed : October 6, 2000
For : PROTEINASE K RESISTANT SURFACE PROTEIN OF
NEISSERIA MENINGITIDIS

Examiner: : Albert Mark Navarro
Art Unit : 1645
Docket No. : 484112.417C1
Date : February 15, 2007

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Information Disclosure Statement. Copies of cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of any other cited references are enclosed. With respect to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the U.S. Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of that is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed; however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Mae Joanne Rosok
Registration No. 48,903

MJR:lw

Enclosures:

Information Disclosure Statement
Cited References (16)

701 Fifth Avenue, Suite 5400
Seattle, Washington 98104
Phone: (206) 622-4900
Fax: (206) 682-6031

906885_1.DOC

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

484112.417C1

APPLICATION NO.

09/684,883

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS

Bernard R. Brodeur

FILING DATE

October 6, 2000

GROUP ART UNIT

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AB	0301992 B1	5/24/95	EP		
	AC	0474313 B1	4/23/97	EP		
	AD					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AE	Aho et al., "A Comparative Analysis of Pilin Genes from Pathogenic and Nonpathogenic <i>Neisseria</i> Species," <i>Microbial Pathogenesis</i> 28:81-88, 2000.
	AF	Bernardini et al., "Proteome Analysis of <i>Neisseria meningitidis</i> Serogroup A," <i>Proteomics</i> 4:2893-2926, 2004.
	AG	Bhattacharjee et al., "Purification and Characterization of H.8 Antigen from Group B <i>Neisseria meningitidis</i> ," <i>Infection and Immunity</i> 56(4):773-778, 1988.
	AH	Bjune et al., "Effect of Outer Membrane Vesicle Vaccine Against Group B Meningococcal Disease in Norway," <i>The Lancet</i> 338(8775):1093-1096, 1991.
	AI	Drocourt et al., "Nucleotide Sequence of the Xylose Isomerase Gene from <i>Streptomyces violaceoniger</i> ," <i>Nucleic Acids Research</i> 16(19):9337, 1988.
	AJ	Frasch et al., "Immune Responses of Adults and Children to Group B <i>Neisseria meningitidis</i> Outer Membrane Protein Vaccines," in <i>Bacterial Vaccines</i> 262-272, 1987.
	AK	Frasch et al., "Outer Membrane Proteins of <i>Neisseria Meningitidis</i> : Structure and Importance in Meningococcal Disease," <i>Clinical and Investigative Medicine</i> 9(2):101-107, 1986.
	AL	Gotschlich et al., "Human Immunity to the Meningococcus," <i>The Journal of Experimental Medicine</i> 129(6):1349-1365, 1969.
	AM	Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations," <i>Journal of Molecular Biology</i> 183:1-12, 1985.
	AN	Mandrell et al., "Human Immune Response to Meningococcal Outer Membrane Protein Epitopes after Natural Infection or Vaccination," <i>Infection and Immunity</i> 57(5):1590-1598, 1989.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Date: February 15, 2007

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICESECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)ATTY. DOCKET NO.
484112.417C1APPLICATION NO.
09/684,883

APPLICANTS

Bernard R. Brodeur


FILING DATE

October 6, 2000

GROUP ART UNIT

1645

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)



Martin et al., "Highly Conserved *Neisseria meningitidis* Surface Protein Confers Protection against Experimental Infection," *Journal of Experimental Medicine* 185(7):1173-1183, 1997.

BB

Saukkonen et al., "Comparative Evaluation of Potential Components for Group B Meningococcal Vaccine by Passive Protection in the Infant Rat and *in vitro* Bactericidal Assay," *Vaccine* 7:325-328, 1989.

BC

Saukkonen et al., "Protective Efficacy of Monoclonal Antibodies to Class 1 and Class 3 Outer Membrane Proteins of *Neisseria meningitidis* B:15:P1.16 in Infant Rat Infection Model: New Prospects for Vaccine Development," *Microbial Pathogenesis* 3:261-267, 1987.

BD

Skevakis et al., "Class-Specific Human Bactericidal Antibodies to Capsular and Noncapsular Surface Antigens of *Neisseria meningitidis*," *The Journal of Infectious Diseases* 149(3):387-396, 1984.

BE

BF

BG

BH

BI

BJ

BK

BL

BM

BN

BO

BP

BQ

BR

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).